Welcome to our dedicated page for Milestone Scient news (Ticker: MLSS), a resource for investors and traders seeking the latest updates and insights on Milestone Scient stock.
Milestone Scient (MLSS) delivers innovative computer-controlled anesthetic systems designed to improve patient comfort in dental and medical procedures. This dedicated news hub provides real-time updates on the company’s technological advancements, regulatory milestones, and strategic partnerships.
Access authoritative information on MLSS’s global expansion across 25+ countries, product innovations like the CompuDent and CompuMed systems, and financial performance. The curated content serves investors and healthcare professionals seeking to monitor the company’s impact on pain management technology.
Key updates include FDA clearances, clinical trial results, partnership announcements with medical institutions, and market penetration strategies. All content is sourced directly from official company communications to ensure accuracy and timeliness.
Bookmark this page for streamlined access to MLSS’s latest developments, enabling data-driven insights into its role in advancing precision anesthetic delivery worldwide.
Milestone Scientific Inc. (MLSS) announced two new distribution agreements with Atlanta Dental and Nashville Dental for its Wand® Single Tooth Anesthesia (STA) System. This expands its distribution network in the U.S. to four independent distributors within a month, demonstrating growing market demand for its dental instruments. CEO Arjan Haverhals emphasized the significance of these distributors in boosting sales and supporting dental practices. The company aims to implement a three-year strategy to expand globally and enhance marketing efforts for future growth.
Milestone Scientific (NYSE American: MLSS) announced the receipt of a Notice of Allowance from the USPTO for a patent related to the disposable component of its CompuFlo® Instrument. This patent aims to enhance safety and control through an embedded micro-chip security feature, preventing unauthorized reuse of disposables. Dr. Mark Hochman emphasized the patent's importance for long-term financial success and the company's leadership in the market, holding over 20 related patents.
Milestone Scientific (NYSE American:MLSS) has announced new agreements with US Dental Depot and IQ Dental Supply to distribute its Wand® Single Tooth Anesthesia (STA) System. These agreements enhance coverage in Florida, New York, and New Jersey, indicating a rebound in demand for the product. CEO Arjan Haverhals expressed optimism about the partnerships, while Interim CEO Leonard Osser highlighted a decentralized sales strategy aimed at targeting independent distributors. These moves are expected to drive sales growth in the dental market.
Milestone Scientific (NYSE American: MLSS) has initiated sales of CompuFlo® Epidural and CathCheck disposables to Regional Medical Center (RMC) in South Carolina. This follows successful testing at RMC and aligns with Milestone's strategy to enhance revenue through disposable sales. Interim CEO Leonard Osser noted that the company’s sales pipeline is the strongest in its history, and they aim to establish CompuFlo as the standard in labor and delivery anesthesia across the U.S.
Milestone Scientific (NYSE American: MLSS) has announced a distribution agreement with Bitmedical AG to market its CompuFlo Epidural Instrument and CathCheck System in Switzerland and Austria. This partnership aims to leverage Bitmedical's expertise in medical device distribution to enhance market presence. The CompuFlo system is noted for its precision in epidural procedures, potentially reducing complications and time for healthcare providers. The agreement highlights the company's strategy to penetrate European markets effectively.
Milestone Scientific (NYSE American: MLSS) announced that Interim CEO Leonard Osser has completed a share sale to cover option costs and taxes, resulting in an increase in his common stock holdings. Osser has submitted Form 4s detailing these transactions and stated he has no plans for further sales. Milestone Scientific specializes in developing computerized drug delivery instruments using its proprietary technology for various medical applications. The company emphasizes its focus on innovation in painless injection technology.
Milestone Scientific (NYSE American: MLSS) has raised its revenue guidance for Q4 2020 to over $2 million, marking a 67% increase from $1.2 million in Q3 2020. This optimistic outlook is attributed to a recovery in the dental sector as dental offices reopen. Notably, this figure excludes recent sales of approximately $450,000 to a Chinese distributor. The company is also gaining traction with its CompuFlo® Epidural System, having started sales of disposables to the University of Texas Medical Branch, with plans to expand to more hospitals.
Milestone Scientific (NYSE American: MLSS) released a survey revealing insights from Board Certified Anesthesiologists regarding the future of anesthesiology. Conducted by the Schlesinger Group, the survey found that 56% of anesthesiologists feel time pressures affect patient care, and 84% believe their skills are underutilized. Notably, 96% emphasize the need for new technologies. Milestone aims to lead this change with products like the CompuFlo Epidural System, which could reduce procedure complications and costs. A webinar detailing these findings is scheduled for January 12, 2021.
Milestone Scientific Inc. (MLSS) has initiated sales of its CompuFlo disposables to the University of Texas Medical Branch (UTMB), following a purchase order received in late 2020. The CompuFlo system is designed to enhance safety and efficiency in epidural procedures, reducing complication rates and anesthesia time. It is projected to deliver significant economic benefits, with a study indicating an average savings of $504 per hospital stay compared to traditional methods. Both hospital and physician responses have been positive, suggesting a favorable outlook for future commercial opportunities.
Milestone Scientific (NYSE American:MLSS) announced that Interim CEO Leonard Osser intends to exercise up to 336,970 options. He plans to sell some shares to fund the options and cover taxes, but this will increase his total common stock holdings. Osser confirmed he will not sell additional shares. The company specializes in innovative, computerized drug delivery systems designed to provide painless injections for medical, dental, and cosmetic applications.
FAQ
What is the current stock price of Milestone Scient (MLSS)?
What is the market cap of Milestone Scient (MLSS)?
